AVEO Pharmaceuticals Operating Income 2009-2021 | AVEO

AVEO Pharmaceuticals operating income from 2009 to 2021. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
AVEO Pharmaceuticals Annual Operating Income
(Millions of US $)
2020 $-39
2019 $-0
2018 $-25
2017 $-29
2016 $-29
2015 $-12
2014 $-50
2013 $-104
2012 $-112
2011 $34
2010 $-56
2009 $-41
2008 $-31
AVEO Pharmaceuticals Quarterly Operating Income
(Millions of US $)
2021-06-30 $-15
2021-03-31 $-19
2020-12-31 $-13
2020-09-30 $-8
2020-06-30 $-7
2020-03-31 $-11
2019-12-31 $-7
2019-09-30 $19
2019-06-30 $-5
2019-03-31 $-8
2018-12-31 $-6
2018-09-30 $-5
2018-06-30 $-7
2018-03-31 $-7
2017-12-31 $-10
2017-09-30 $-2
2017-06-30 $-9
2017-03-31 $-8
2016-12-31 $-9
2016-09-30 $-6
2016-06-30 $-7
2016-03-31 $-7
2015-12-31 $-6
2015-09-30 $8
2015-06-30 $-5
2015-03-31 $-10
2014-12-31 $-13
2014-09-30 $-14
2014-06-30 $-17
2014-03-31 $-6
2013-12-31 $-16
2013-09-30 $-24
2013-06-30 $-31
2013-03-31 $-33
2012-12-31 $-21
2012-09-30 $-29
2012-06-30 $-29
2012-03-31 $-33
2011-12-31 $-24
2011-09-30 $-23
2011-06-30 $-5
2011-03-31 $86
2010-12-31 $-10
2010-09-30 $-18
2010-06-30 $-14
2010-03-31 $-14
2009-12-31 $-10
2009-09-30 $-13
2009-06-30 $-9
2009-03-31 $-9
2008-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.237B $0.006B
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71